KR102530925B1 - 신규 보툴리눔 신경독소 및 그의 유도체 - Google Patents

신규 보툴리눔 신경독소 및 그의 유도체 Download PDF

Info

Publication number
KR102530925B1
KR102530925B1 KR1020197003414A KR20197003414A KR102530925B1 KR 102530925 B1 KR102530925 B1 KR 102530925B1 KR 1020197003414 A KR1020197003414 A KR 1020197003414A KR 20197003414 A KR20197003414 A KR 20197003414A KR 102530925 B1 KR102530925 B1 KR 102530925B1
Authority
KR
South Korea
Prior art keywords
delete delete
bont
asn
ile
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197003414A
Other languages
English (en)
Korean (ko)
Other versions
KR20190026834A (ko
Inventor
폴 스텐마크
민 동
시카이 장
Original Assignee
칠드런'즈 메디컬 센터 코포레이션
폴 스텐마크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칠드런'즈 메디컬 센터 코포레이션, 폴 스텐마크 filed Critical 칠드런'즈 메디컬 센터 코포레이션
Publication of KR20190026834A publication Critical patent/KR20190026834A/ko
Application granted granted Critical
Publication of KR102530925B1 publication Critical patent/KR102530925B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
KR1020197003414A 2016-07-08 2017-07-07 신규 보툴리눔 신경독소 및 그의 유도체 Active KR102530925B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662360239P 2016-07-08 2016-07-08
US62/360,239 2016-07-08
PCT/US2017/041255 WO2018009903A2 (en) 2016-07-08 2017-07-07 A novel botulinum neurotoxin and its derivatives

Publications (2)

Publication Number Publication Date
KR20190026834A KR20190026834A (ko) 2019-03-13
KR102530925B1 true KR102530925B1 (ko) 2023-05-11

Family

ID=59384231

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197003414A Active KR102530925B1 (ko) 2016-07-08 2017-07-07 신규 보툴리눔 신경독소 및 그의 유도체

Country Status (22)

Country Link
US (2) US11286473B2 (https=)
EP (2) EP3481852B1 (https=)
JP (2) JP7158371B2 (https=)
KR (1) KR102530925B1 (https=)
CN (1) CN109803980B (https=)
AU (2) AU2017292922B9 (https=)
BR (1) BR112019000278A2 (https=)
CA (1) CA3030155A1 (https=)
DK (1) DK3481852T5 (https=)
EA (1) EA201990229A1 (https=)
ES (1) ES2939001T3 (https=)
FI (1) FI3481852T3 (https=)
HU (1) HUE061429T2 (https=)
IL (2) IL263754B2 (https=)
MX (1) MX2019000151A (https=)
NZ (1) NZ749810A (https=)
PL (1) PL3481852T3 (https=)
PT (1) PT3481852T (https=)
SG (2) SG10201912102WA (https=)
UA (1) UA125965C2 (https=)
WO (1) WO2018009903A2 (https=)
ZA (1) ZA201900341B (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3202903B1 (en) 2010-12-22 2020-02-12 President and Fellows of Harvard College Continuous directed evolution
WO2014079495A1 (en) * 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
US10179911B2 (en) 2014-01-20 2019-01-15 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
US20180140685A1 (en) * 2015-04-24 2018-05-24 Consiglio Nazionale Delle Ricerche A new therapeutic use of the botulinum neurotoxin serotype a
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
US11242515B2 (en) * 2016-05-16 2022-02-08 President And Fellows Of Harvard College Method for purification and activation of botulinum neurotoxin
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11040090B2 (en) * 2016-12-08 2021-06-22 Prime Bio, Inc Botulinum neurotoxin compositions
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
AU2018321405A1 (en) 2017-08-25 2020-03-05 Ipsen Biopharm Ltd. Evolution of BoNT peptidases
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
US12098169B2 (en) * 2017-09-29 2024-09-24 Children's Medical Center Corporation Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof
WO2019152380A1 (en) 2018-01-30 2019-08-08 Children's Medical Center Corporation Production of botulinum neurotoxins using bacillus systems
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
JP7604365B2 (ja) 2018-09-28 2024-12-23 イプセン バイオファーム リミテッド 細胞ベースのクロストリジウム神経毒アッセイ
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
WO2020219358A2 (en) * 2019-04-17 2020-10-29 Children's Medical Center Corporation Catalytically inactive botulinum neurotoxin-like toxins and uses thereof
GB201907016D0 (en) 2019-05-17 2019-07-03 Ipsen Biopharm Ltd Screening method to determine suitability for participation in a clinical trial
US20220259269A1 (en) * 2019-07-15 2022-08-18 President And Fellows Of Harvard College Evolved botulinum neurotoxins and uses thereof
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
CN110938150B (zh) * 2019-12-16 2021-08-31 中国人民解放军军事科学院军事医学研究院 E型肉毒毒素重组l-hn抗原的制备方法及其应用
KR102610179B1 (ko) * 2019-12-18 2023-12-05 엠브릭스 주식회사 보툴리눔 신경 독소의 안전한 제조 방법
WO2022140249A1 (en) * 2020-12-21 2022-06-30 Children's Medical Center Corporation Improved receptor-binding domain of botulinum neurotoxin a and uses thereof
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
CN113495106B (zh) * 2021-02-10 2023-08-25 中国人民解放军军事科学院军事医学研究院 样品检测方法
CN114957482B (zh) * 2021-02-26 2024-09-24 重庆誉颜制药有限公司 一种经修饰的神经毒素的单链多肽及其用途
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2022197623A1 (en) * 2021-03-15 2022-09-22 Children's Medical Center Corporation Engineered botulinum neurotoxin a protease domain with improved efficacy
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
WO2022208091A1 (en) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
JP7659653B2 (ja) 2021-03-30 2025-04-09 イプセン バイオファーム リミテッド 疼痛及び炎症性障害の処置
US20240216487A1 (en) * 2021-04-26 2024-07-04 Shanghaitech University Intramuscular compositions of botulinum neurotoxins
CA3228426A1 (en) * 2021-08-06 2023-02-09 Kao Corporation Nucleic acid structure utilizing snare
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
WO2023089343A1 (en) 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
EP4537850A1 (en) * 2022-06-10 2025-04-16 Medytox Inc. Composition for stabilizing botulinum neurotoxin, botulinum neurotoxin formulation containing same, and polypeptides for use therein
CN115785237B (zh) * 2022-09-01 2023-06-16 上海蓝晶生物科技有限公司 一种重组肉毒杆菌毒素及其制备方法
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
JP2025534349A (ja) 2022-09-30 2025-10-15 イプセン バイオファーム リミテッド 膀胱痛症候群の治療
GB202307439D0 (en) 2023-05-18 2023-07-05 Ipsen Biopharm Ltd Treatment of a headache disorder with botylinum neurotoxin a
CN116813727B (zh) * 2023-06-08 2025-06-06 苏州德进生物制药有限公司 一种a型肉毒毒素的制备方法及其应用
WO2025093844A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
WO2025093845A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay
CN118388606B (zh) * 2024-04-25 2025-09-23 武汉大学 一种结合蛋白Bntifitin及其在制备用于治疗冠状病毒感染的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014854A1 (en) 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins
WO2012041761A2 (en) 2010-09-28 2012-04-05 Merz Pharma Gmbh & Co. Kgaa Botulinum neurotoxin polypeptides exhibiting a prolonged activity
WO2013180799A1 (en) 2012-05-30 2013-12-05 President And Fellows Of Harvard College Engineered botulinum neurotoxin

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
PT1086702E (pt) 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US8137924B2 (en) * 2003-12-19 2012-03-20 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
US7700738B2 (en) * 2005-01-27 2010-04-20 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP1871789B1 (en) * 2005-03-15 2013-11-06 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
EP2505592A1 (en) * 2006-07-11 2012-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
CN100577149C (zh) * 2006-12-21 2010-01-06 北京民海生物科技有限公司 一种治疗用a型肉毒毒素冻干粉针剂新型冻干保护剂配方
KR20120107988A (ko) * 2009-12-16 2012-10-04 알러간, 인코포레이티드 통합된 프로테아제 절단 부위 결합 도메인을 포함하는 변형 클로스트리듐 독소
RU2561465C2 (ru) * 2010-05-20 2015-08-27 Аллерган, Инк. Разрушаемые клостридиальные токсины
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
CN107108703B (zh) * 2015-01-09 2022-09-23 益普生生物创新有限公司 阳离子神经毒素
PT3274364T (pt) * 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
GB201505306D0 (en) * 2015-03-27 2015-05-13 Ipsen Biopharm Ltd Chimeric polypeptides
US10704035B2 (en) * 2015-08-27 2020-07-07 President And Fellows Of Harvard College Compositions and methods for treatment of pain
CN109476713A (zh) * 2016-06-08 2019-03-15 儿童医学中心公司 工程改造的肉毒杆菌神经毒素
EP3481852B1 (en) 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
EP3504226A1 (en) * 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
EP3312290A1 (en) * 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
EP3529371B1 (en) * 2016-10-21 2022-06-22 Toxogen GmbH A functional detection assay devoid of antibodies for serotyping of botulinum neurotoxins
US20190364907A1 (en) 2017-07-21 2019-12-05 The Regents Of The University Of California Compositions of mosquitocidal clostridial proteins and methods of use
US12098169B2 (en) * 2017-09-29 2024-09-24 Children's Medical Center Corporation Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof
WO2019152380A1 (en) * 2018-01-30 2019-08-08 Children's Medical Center Corporation Production of botulinum neurotoxins using bacillus systems
WO2019243376A1 (en) * 2018-06-18 2019-12-26 Ipsen Biopharm Limited Intramuscular injection of botulinum toxin for the treatment of vulvodynia
JP7604365B2 (ja) * 2018-09-28 2024-12-23 イプセン バイオファーム リミテッド 細胞ベースのクロストリジウム神経毒アッセイ
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014854A1 (en) 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins
WO2012041761A2 (en) 2010-09-28 2012-04-05 Merz Pharma Gmbh & Co. Kgaa Botulinum neurotoxin polypeptides exhibiting a prolonged activity
WO2013180799A1 (en) 2012-05-30 2013-12-05 President And Fellows Of Harvard College Engineered botulinum neurotoxin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clostridium botulinum DNA, complete genome, strain: 111, GenBank: AP014696.1(2015.02.21., https://ncbi.nlm.nih.gov/nuccore/AP014696.1) 1부.*
Putative botulinum neurotoxin [Clostridium botulinum], GenBank: BAQ12790.1(2015.02.21., https://ncbi.nlm.nih.gov/protein/BAQ12790) 1부.*

Also Published As

Publication number Publication date
EP3481852A2 (en) 2019-05-15
JP2019528042A (ja) 2019-10-10
US11286473B2 (en) 2022-03-29
CN109803980A (zh) 2019-05-24
AU2022203264A1 (en) 2022-06-02
WO2018009903A2 (en) 2018-01-11
JP7402916B2 (ja) 2023-12-21
US20190136216A1 (en) 2019-05-09
AU2017292922B2 (en) 2022-02-17
IL263754B2 (en) 2023-04-01
US20200224185A9 (en) 2020-07-16
PT3481852T (pt) 2023-02-22
ES2939001T3 (es) 2023-04-18
JP2022119794A (ja) 2022-08-17
CA3030155A1 (en) 2018-01-11
JP7158371B2 (ja) 2022-10-21
DK3481852T3 (da) 2023-02-27
US20220177867A1 (en) 2022-06-09
ZA201900341B (en) 2023-07-26
SG10201912102WA (en) 2020-02-27
IL298102B1 (en) 2025-05-01
EP4212545A1 (en) 2023-07-19
KR20190026834A (ko) 2019-03-13
EA201990229A1 (ru) 2019-06-28
IL263754A (en) 2019-01-31
IL298102B2 (en) 2025-09-01
EP3481852B1 (en) 2022-12-07
UA125965C2 (uk) 2022-07-20
SG11201811338VA (en) 2019-01-30
BR112019000278A2 (pt) 2019-04-24
IL298102A (en) 2023-01-01
HUE061429T2 (hu) 2023-06-28
CN109803980B (zh) 2023-07-25
WO2018009903A3 (en) 2018-02-15
MX2019000151A (es) 2019-08-29
DK3481852T5 (da) 2024-09-02
IL263754B (en) 2022-12-01
FI3481852T3 (fi) 2023-03-19
AU2017292922A1 (en) 2019-01-31
AU2022203264B2 (en) 2024-02-22
PL3481852T3 (pl) 2023-07-24
NZ749810A (en) 2025-12-19
AU2017292922B9 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
KR102530925B1 (ko) 신규 보툴리눔 신경독소 및 그의 유도체
US12098169B2 (en) Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof
US11104891B2 (en) Engineered botulinum neurotoxins
US20240082369A1 (en) Improved receptor-binding domain of botulinum neurotoxin a and uses thereof
WO2022197623A1 (en) Engineered botulinum neurotoxin a protease domain with improved efficacy
US20260103697A1 (en) Modified bont/a2 receptor-binding domains
HK40008476B (en) A novel botulinum neurotoxin and its derivatives
HK40008476A (en) A novel botulinum neurotoxin and its derivatives
EA041568B1 (ru) Новый ботулинический нейротоксин и его производные

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4